Galapagos to provide medicinal chemistry services to AstraZeneca

By Lisa Kerner

Charlotte, N.C., Aug. 3 - Galapagos NV said its service division, BioFocus DPI, has entered into a drug discovery collaboration with AstraZeneca to perform hit-to-lead medicinal chemistry services for AstraZeneca's respiratory and inflammatory drug discovery programs.

The total contract value for Galapagos is €650,000, according to a company news release.

Galapagos is a Mechelen, Belgium-based genomics-based drug discovery company.

AstraZeneca is an international pharmaceutical and health care services company located in Wilmington, Del.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.